Requirement of divalent galactoside-binding activity of ecalectin/galectin-9 for eosinophil chemoattraction

Nobuko Matsushita, Nozomu Nishi, Masako Seki, Ryoji Matsumoto, Ichiro Kuwabara, Fu-Tong Liu, Yuiro Hata, Takanori Nakamura, Mitsuomi Hirashima

Research output: Contribution to journalArticle

113 Citations (Scopus)

Abstract

We have previously isolated and cloned a novel eosinophil chemoattractant (ECA) from a human T-cell-derived expression library. This ECA, termed ecalectin, is a variant of human galectin-9, a member of a β- galactoside binding animal lectin family, which contains two conserved carbohydrate recognition domains (CRDs). In the present study, we addressed whether carbohydrate binding activity is required for the ECA activity of ecalectin and whether both CRDs are essential for this activity. Recombinant full-length wild-type ecalectin (ecalectin-WT) and N-terminal and C-terminal CRD (ecalectin-NT and -CT, respectively) were generated. All of these recombinant proteins exhibited affinity for lactose, a property shared by galectins, but ecalectin-WT exhibited substantially higher hemagglutination activities than ecalectin-NT and -CT. Furthermore, ecalectin-WT showed over 100-fold higher ECA activity than ecalectin-NT and -CT; combination of recombinant domain fragments did not reconstitute the ECA and hemagglutination activities of the full-length protein. ECA activity of ecalectin-WT was inhibited by lactose in a dose-dependent manner. Site- directed mutation of positions Arg55 of ecalectin-NT and Arg239 of ecalectin-CT to an aspartic acid residue resulted in the loss of both lactose-binding and ECA activities. We conclude that divalent galactoside- binding activity is required for eosinophil chemoattraction by ecalectin.

Original languageEnglish (US)
Pages (from-to)8355-8360
Number of pages6
JournalJournal of Biological Chemistry
Volume275
Issue number12
DOIs
StatePublished - Mar 24 2000

Fingerprint

Galectins
Galactosides
Chemotactic Factors
Eosinophils
Lactose
Carbohydrates
Hemagglutination
T-cells
Recombinant Proteins
Lectins
Aspartic Acid
T-Lymphocytes
Mutation

ASJC Scopus subject areas

  • Biochemistry

Cite this

Matsushita, N., Nishi, N., Seki, M., Matsumoto, R., Kuwabara, I., Liu, F-T., ... Hirashima, M. (2000). Requirement of divalent galactoside-binding activity of ecalectin/galectin-9 for eosinophil chemoattraction. Journal of Biological Chemistry, 275(12), 8355-8360. https://doi.org/10.1074/jbc.275.12.8355

Requirement of divalent galactoside-binding activity of ecalectin/galectin-9 for eosinophil chemoattraction. / Matsushita, Nobuko; Nishi, Nozomu; Seki, Masako; Matsumoto, Ryoji; Kuwabara, Ichiro; Liu, Fu-Tong; Hata, Yuiro; Nakamura, Takanori; Hirashima, Mitsuomi.

In: Journal of Biological Chemistry, Vol. 275, No. 12, 24.03.2000, p. 8355-8360.

Research output: Contribution to journalArticle

Matsushita, N, Nishi, N, Seki, M, Matsumoto, R, Kuwabara, I, Liu, F-T, Hata, Y, Nakamura, T & Hirashima, M 2000, 'Requirement of divalent galactoside-binding activity of ecalectin/galectin-9 for eosinophil chemoattraction', Journal of Biological Chemistry, vol. 275, no. 12, pp. 8355-8360. https://doi.org/10.1074/jbc.275.12.8355
Matsushita, Nobuko ; Nishi, Nozomu ; Seki, Masako ; Matsumoto, Ryoji ; Kuwabara, Ichiro ; Liu, Fu-Tong ; Hata, Yuiro ; Nakamura, Takanori ; Hirashima, Mitsuomi. / Requirement of divalent galactoside-binding activity of ecalectin/galectin-9 for eosinophil chemoattraction. In: Journal of Biological Chemistry. 2000 ; Vol. 275, No. 12. pp. 8355-8360.
@article{8970c087edf54e399c41c7f9d584d997,
title = "Requirement of divalent galactoside-binding activity of ecalectin/galectin-9 for eosinophil chemoattraction",
abstract = "We have previously isolated and cloned a novel eosinophil chemoattractant (ECA) from a human T-cell-derived expression library. This ECA, termed ecalectin, is a variant of human galectin-9, a member of a β- galactoside binding animal lectin family, which contains two conserved carbohydrate recognition domains (CRDs). In the present study, we addressed whether carbohydrate binding activity is required for the ECA activity of ecalectin and whether both CRDs are essential for this activity. Recombinant full-length wild-type ecalectin (ecalectin-WT) and N-terminal and C-terminal CRD (ecalectin-NT and -CT, respectively) were generated. All of these recombinant proteins exhibited affinity for lactose, a property shared by galectins, but ecalectin-WT exhibited substantially higher hemagglutination activities than ecalectin-NT and -CT. Furthermore, ecalectin-WT showed over 100-fold higher ECA activity than ecalectin-NT and -CT; combination of recombinant domain fragments did not reconstitute the ECA and hemagglutination activities of the full-length protein. ECA activity of ecalectin-WT was inhibited by lactose in a dose-dependent manner. Site- directed mutation of positions Arg55 of ecalectin-NT and Arg239 of ecalectin-CT to an aspartic acid residue resulted in the loss of both lactose-binding and ECA activities. We conclude that divalent galactoside- binding activity is required for eosinophil chemoattraction by ecalectin.",
author = "Nobuko Matsushita and Nozomu Nishi and Masako Seki and Ryoji Matsumoto and Ichiro Kuwabara and Fu-Tong Liu and Yuiro Hata and Takanori Nakamura and Mitsuomi Hirashima",
year = "2000",
month = "3",
day = "24",
doi = "10.1074/jbc.275.12.8355",
language = "English (US)",
volume = "275",
pages = "8355--8360",
journal = "Journal of Biological Chemistry",
issn = "0021-9258",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "12",

}

TY - JOUR

T1 - Requirement of divalent galactoside-binding activity of ecalectin/galectin-9 for eosinophil chemoattraction

AU - Matsushita, Nobuko

AU - Nishi, Nozomu

AU - Seki, Masako

AU - Matsumoto, Ryoji

AU - Kuwabara, Ichiro

AU - Liu, Fu-Tong

AU - Hata, Yuiro

AU - Nakamura, Takanori

AU - Hirashima, Mitsuomi

PY - 2000/3/24

Y1 - 2000/3/24

N2 - We have previously isolated and cloned a novel eosinophil chemoattractant (ECA) from a human T-cell-derived expression library. This ECA, termed ecalectin, is a variant of human galectin-9, a member of a β- galactoside binding animal lectin family, which contains two conserved carbohydrate recognition domains (CRDs). In the present study, we addressed whether carbohydrate binding activity is required for the ECA activity of ecalectin and whether both CRDs are essential for this activity. Recombinant full-length wild-type ecalectin (ecalectin-WT) and N-terminal and C-terminal CRD (ecalectin-NT and -CT, respectively) were generated. All of these recombinant proteins exhibited affinity for lactose, a property shared by galectins, but ecalectin-WT exhibited substantially higher hemagglutination activities than ecalectin-NT and -CT. Furthermore, ecalectin-WT showed over 100-fold higher ECA activity than ecalectin-NT and -CT; combination of recombinant domain fragments did not reconstitute the ECA and hemagglutination activities of the full-length protein. ECA activity of ecalectin-WT was inhibited by lactose in a dose-dependent manner. Site- directed mutation of positions Arg55 of ecalectin-NT and Arg239 of ecalectin-CT to an aspartic acid residue resulted in the loss of both lactose-binding and ECA activities. We conclude that divalent galactoside- binding activity is required for eosinophil chemoattraction by ecalectin.

AB - We have previously isolated and cloned a novel eosinophil chemoattractant (ECA) from a human T-cell-derived expression library. This ECA, termed ecalectin, is a variant of human galectin-9, a member of a β- galactoside binding animal lectin family, which contains two conserved carbohydrate recognition domains (CRDs). In the present study, we addressed whether carbohydrate binding activity is required for the ECA activity of ecalectin and whether both CRDs are essential for this activity. Recombinant full-length wild-type ecalectin (ecalectin-WT) and N-terminal and C-terminal CRD (ecalectin-NT and -CT, respectively) were generated. All of these recombinant proteins exhibited affinity for lactose, a property shared by galectins, but ecalectin-WT exhibited substantially higher hemagglutination activities than ecalectin-NT and -CT. Furthermore, ecalectin-WT showed over 100-fold higher ECA activity than ecalectin-NT and -CT; combination of recombinant domain fragments did not reconstitute the ECA and hemagglutination activities of the full-length protein. ECA activity of ecalectin-WT was inhibited by lactose in a dose-dependent manner. Site- directed mutation of positions Arg55 of ecalectin-NT and Arg239 of ecalectin-CT to an aspartic acid residue resulted in the loss of both lactose-binding and ECA activities. We conclude that divalent galactoside- binding activity is required for eosinophil chemoattraction by ecalectin.

UR - http://www.scopus.com/inward/record.url?scp=0034708434&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034708434&partnerID=8YFLogxK

U2 - 10.1074/jbc.275.12.8355

DO - 10.1074/jbc.275.12.8355

M3 - Article

C2 - 10722666

AN - SCOPUS:0034708434

VL - 275

SP - 8355

EP - 8360

JO - Journal of Biological Chemistry

JF - Journal of Biological Chemistry

SN - 0021-9258

IS - 12

ER -